Netis is indicated for the treatment of symptoms associated with allergic conditions such as-

• perennial allergic rhinitis,
• seasonal allergic rhinitis, 
• chronic idiopathic urticaria.

This preparation contains levocetirizine dihydrochloride. Levocetirizine is the active (levo) isomer of cetirizine. It is a highly effective and well-tolerated, non-sedating antihistamine with strong antiallergic properties. Levocetirizine has approximately twice the affinity for H1 receptors compared to cetirizine. It acts rapidly and has a prolonged duration of action, allowing for once-daily dosing.

Adult and children 12 years of age and older: The recommended dose is 5 mg once daily.

Children 6 to 11 years of age: The recommended dose is 2.5 mg (½ tablet or 1 teaspoon oral solution) once daily.

Children 6 months to 5 years of age: The recommended dose is 1.25 mg (½ teaspoon oral solution) once daily.

Pediatric use: The recommended dose for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in patients 6 months to 17 years of age is based on extrapolation of efficacy from adults 18 years of age and older.

Geriatric use: In clinical studies, each approved indication did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently than younger patients. Hepatic impairment: No dosage adjustment is required in patients with solely hepatic impairment.

Renal impairment:

• Mild renal impairment (creatinine clearance: 50-80 ml/min): a dose of 2.5 mg once daily is recommended.
• Moderate renal impairment (creatinine clearance: 30-50 ml/min): a dose of 2.5 mg once every other day is
• recommended.
• Severe renal impairment (creatinine clearance: 10-30 ml/min): a dose of 2.5 mg twice weekly (administered
• once every 3-4 days) is recommended.
• End-stage renal disease patients (creatinine clearance: <10 ml/min) and patients undergoing hemodialysis:
• should not receive Levocetirizine.

Contraindicated in patients with hypersensitivity to levocetirizine, cetirizine, or its parent compound hydroxyzine. Levocetirizine should not be used in patients with severe renal impairment (creatinine clearance <10 mL/min).

Levocetirizine is generally well tolerated. However, rare adverse effects such as headache, dry mouth, fatigue, and skin rash have been reported.

Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. As animal reproduction studies do not always predict human response, levocetirizine should be used during pregnancy only if clearly necessary. Levocetirizine is excreted in breast milk; therefore, its use is not recommended in nursing mothers.

Use with caution in patients with epilepsy or those at risk of seizures, in individuals with renal impairment, and during pregnancy and lactation.

No clinically significant adverse events have been reported in cases of overdose. However, if an overdose occurs, symptomatic and supportive treatment is recommended.

Non-sedating antihistamines

Store at a temperature not exceeding 30°C in a dry place, protected from light.